Company Filing History:
Years Active: 2000-2019
Title: Innovations of Behrooz G Sharifi
Introduction
Behrooz G Sharifi is a prominent inventor based in Woodland Hills, CA. He has made significant contributions to the field of gene therapy and cardiovascular health, holding a total of five patents. His work focuses on innovative methods to treat atherosclerosis and improve gene transfer efficiency.
Latest Patents
One of Sharifi's latest patents involves a method for atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using Apo A-I Milano gene transfer. This invention describes a technique to change the phenotype of monocytes and macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype. The method includes providing a composition with a recombinant adeno-associated virus (rAAV) vector that encodes ApoA-I Milano or a fragment thereof. By administering this composition to a mammal, the phenotype of monocytes or macrophages can be altered, potentially treating atherosclerosis. Another significant patent focuses on an effective vector platform for gene transfer and gene therapy. This invention reveals that mutations of serine residues in an AAV capsid can lead to significantly greater transfection efficiency compared to the wild type AAV2 virus. The method improves gene transfer efficiency by inhibiting phosphorylation of specific serine residues in the virus capsid protein.
Career Highlights
Behrooz G Sharifi is affiliated with Cedars-Sinai Medical Center, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on treating cardiovascular diseases through gene therapy.
Collaborations
Sharifi has collaborated with notable colleagues, including Prediman Krishan Shah and Lai Wang, contributing to the advancement of research in his field.
Conclusion
Behrooz G Sharifi's innovative work in gene therapy and atherosclerosis treatment showcases his dedication to improving health outcomes through scientific advancements. His patents reflect a commitment to addressing critical medical challenges.